China's National Medical Products Administration accepted Suzhou Zelgen Biopharmaceuticals' (SHA:688266) marketing application for a new indication of human thyrotropin beta for injection, according to a Shanghai bourse filing on Monday.
The new indication is to use the drug in combination with radioactive iodine for the treatment of patients with differentiated thyroid cancer without distant metastasis.
The pharmaceutical company's shares slipped 1% during the midday trade.